Vanin-1 as a marker for early evaluation of acetaminophen induced acute liver injury

Abstract

Abstract: Objective To investigate the expression and evaluation value of vanin-1 in acute liver injury induced by acetaminophen (APAP). Methods We established the acute liver injury model of mice induced by APAP. The rats were randomly divided into control group and experimental groups treated with various concentrations of APAP (100, 200, 300 mg/kg). The serum alanine aminotransferase (ALT) level, vanin-1 level in serum and in liver were detected. Parallel contrast was conducted between vanin-1 and ALT to analyze the correlation, and to evaluated the value of vanin-1 in the early evaluation of APAP-induced acute liver injury in mice. Results (1) At 12 hours (12h) after the establishment of the model, compared with the control group, serum ALT levels in the APAP treatment groups were significantly higher (P<0.05), which was dose-dependent. (2) At 12h, the expression levels of vanin-1 in serum and liver tissue in the APAP treatment groups were significantly higher than those in the control group (P<0.05), which was dose-dependent. (3) In the early evaluation of acute liver injury, vanin-1 mRNA was correlated with ALT (R>0.9). (4) Compared with ALT, vanin-1 is more sensitive in acute liver injury. Conclusion Vanin-1 is expected to be a marker for the early evaluation of acute liver injury induced by APAP, which needs further research.

Key words: Acute liver injury, Acetaminophen, Vanin-1, Early evaluation, Alanine aminotransferase

ZHEN Li-ying. Vanin-1 as a marker for early evaluation of acetaminophen induced acute liver injury[J]. Chinese Hepatolgy, 2020, 25(7): 679-681.

References

[1] McGill MR, Jaeschke H. Metabolism and disposition of acetaminophen: recent advances in relation to hepatotoxicity and diagnosis. Pharm Res, 2013, 30:2174-2187.
[2] Larson AM, Polson J, Fontana RJ, et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology, 2005, 42:1364-1372.
[3] Sattar N, Scherbakova O, Ford I, et al. Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study. Diabetes, 2004, 53:2855-2860.
[4] Ladue JS, Wroblewski F. The significance of the serum glutamic oxalacetic transaminase activity following acute myocardial infarction. Circulation, 1955, 11:871-877.
[5] Pitari G, Malergue F, Martin F, et al. Pantetheinase activity of membrane-bound Vanin-1: lack of free cysteamine in tissues of Vanin-1 deficient mice. FEBS Lett, 2000, 483:149-154.
[6] Hosohata K, Ando H, Fujimura A. Urinary vanin-1 as a novel biomarker for early detection of drug-induced acute kidney injury. J Pharmacol Exp Ther, 2012, 341:656-662.
[7] Motomura W, Yoshizaki T, Takahashi N, et al. Analysis of vanin-1 upregulation and lipid accumulation in hepatocytes in response to a high-fat diet and free fatty acids. J Clin Biochem Nutr, 2012, 51:163-169.
[8] Moffit JS, Koza-Taylor PH, Holland RD, et al. Differential gene expression in mouse liver associated with the hepatoprotective effect of clofibrate. Toxicol Appl Pharmacol, 2007, 222:169-179.
[9] Jansen PA, Kamsteeg M, Rodijk-Olthuis D, et al. Expression of the vanin gene family in normal and inflamed human skin: induction by proinflammatory cytokines. J Invest Dermatol, 2009, 129:2167-2174.
[10] Hosohata K, Jin D, Takai S, et al. Vanin-1 in renal pelvic urine reflects kidney injury in a rat model of hydronephrosis. Int J Mol Sci,2018, 19,pii: E3186.